SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Pictured: Bayer's office in Berlin, Germany/iStock
Business
Bayer Rolls Out New Operating Model, Eliminates Managerial Staff
The sweeping changes are meant to “reduce hierarchies” and “accelerate decision-making” as Bayer weathers several business crises and continues to suffer from the fallout of its disastrous Monsanto acquisition.
January 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of the U.S. Patent and Trademark
Policy
USPTO Rules Against Seagen in ADC Patent Battle with Daiichi Sankyo
The U.S. Patent and Trademark Office has sided with Daiichi over Seagen in a years-long patent saga concerning a key linker technology used in its blockbuster Enhertu antibody-drug conjugate for cancer.
January 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: GSK laboratories in Dresden, Germany
GSK Raises $1.24B by Selling Stake in Consumer Health Spin-Off Haleon
The British drugmaker on Wednesday said it sold around 300 million shares of Haleon, cutting its shareholding to 4.2%, as it expands its portfolio of specialty medicines, Reuters reported.
January 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: A sign in front of a Takeda building/iSt
FDA
Takeda Gets FDA Label Expansion for HyQvia in Rare Autoimmune Disorder
The FDA on Tuesday extended the label for Takeda’s immune globulin infusion as a maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy.
January 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Illumina signage outside its office in California
Policy
Judge Orders Icahn to Strike Confidential Information from Illumina Lawsuit
Delaware Chancery Court Judge Paul Fioravanti on Tuesday ordered activist investor Carl Icahn to remove confidential information from his lawsuit against legacy Illumina board members.
January 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Illustration depicting large layoffs/iSt
Business
Allakos Axes Half of Its Workforce, Drops Lead Inflammatory Candidate
The biotech Tuesday announced a restructuring plan as its humanized IgG1 antibody lirentelimab failed two Phase II studies in atopic dermatitis and chronic spontaneous urticaria.
January 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Handshake over a deal/iStock, PeopleImag
Business
Pan Orion Invests $415M in Korean Biotech LegoChem, Secures Majority Stake
The snacks and confectionery giant has been seeking to enter the biopharmaceuticals space in recent years.
January 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Large yellow sign boards hoisted on meta
Deals
Alto, Kyverna Join Growing Number of Biotech IPO Filings in 2024
Alto Neuroscience and Kyverna Therapeutics are following in the footsteps of CG Oncology, Metagenomi and Arrivent in seeking initial public offerings this year.
January 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: FDA sign at its office in Washington, DC/iStock, JHVEPhoto
Policy
FDA Action Alert: Satsuma, Theratechnologies and Heron
After a quiet start to 2024, the FDA is expected to decide on three applications over the next two weeks, including one for a nasal powder migraine treatment.
January 12, 2024
 · 
3 min read
 · 
Tristan Manalac
Pictured: FDA sign at its office in Washington, DC/iStock, JHVEPhoto
Policy
FDA Finds No Link Between GLP-1 Drugs and Suicidal Thoughts
The agency nevertheless said that it could not definitively rule out a small risk of suicidal ideation associated with GLP-1 receptor agonists, and that it will continue evaluating the evidence.
January 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Novartis building in Switzerland
Business
Amgen Emerges as Potential Cytokinetics Suitor as Novartis Pulls Away: Reports
Dropping the potential Cytokinetics buy runs contrary to Novartis’ recent dealmaking frenzy, which included the acquisition of Calypso and three research collaborations.
January 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Biogen’s headquarters in Massachusetts
Business
Amid Declining Sales, Biogen Hands MS Drug Fampyra Back to Acorda
Biogen gained exclusive ex-U.S. rights to Ampyra in 2009 and is selling the drug under the brand name Fampyra in international markets.
January 12, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: A silhouette of a woman sitting on the f
DSM-5 Panel Members Received $14.2M in Industry Funding: Study
A new study published in the BMJ found strong financial ties between the pharmaceutical industry and physicians serving as panelists and task force members of the DSM-5.
January 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: A corporate building overlooking a freew
Business
Myrobalan Claims $24M for Portfolio of Neurorestorative Drugs
The Massachusetts–based startup will use the Series A funds to advance its pipeline of oral GPR17, CSF1R and TYK2 candidates.
January 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Woman using eye drops/iStock, eternalcre
Drug Development
Alcon’s Investigational Drops Show Promising Phase III Data in Dry Eye Disease
Patients treated with AR-15512 showed higher rates of at least a 10-mm improvement in unanesthetized Schirmer’s score, a metric of tear production.
January 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More